

# HUNGARY

## Recent and planned developments in pharmaceutical policies 2022/2023

### CHANGES IN PRICING

**Increased tax:**

Medicines with manufacturer price above 10.000 HUF ~ 25 € have to pay temporarily an increased tax (28% instead of 20% of the manufacturer price proportionated to the rate of reimbursement, R&D costs spent in Hungary are deductible)

2022-2023

### CHANGES IN REIMBURSEMENT

**Formerly high priced products moved to the general reimbursement scheme from public procurement process:** TNF- $\alpha$  inhibitors (adalimumab, etanercept, certolizumab pegol, golimumab), abiraterone, enzolutamide, erlotinib, gefitinib, pemetrexed, thalidomide

Dec 2022 -  
Jan 2023

**Changes in the named patient reimbursement scheme**  
New medical and ethical committee was set up to make decision in case of named patient claims.

1 Feb 2023

### OTHER CHANGES

**Unification of software used in health care (prescribing software, hospital software):**

A centrally developed software, integrated to the e-health system is under development and will have to be used by the health care providers in the future.

coming  
years

### SPECIAL TOPIC:

**Developing and implementing pharmaceutical policies in view of the current challenges (soaring inflation, medicine price increases, increasing no. of medicine shortages)**

- 1) **Medicine shortages:**
  - National register to report shortages: in place (mandatory)
  - Export ban / notification for medicines targeted by shortage: no current ban is in place
  - Regulatory measures: no changes
  - Financial measures: no changes
  - Stakeholder involvement: no change
  - Other: nothing
- 2) **Price increases:**
  - a) medicines included in the out-patient reimbursement list: Marketing authorisation holders can submit applications for price increase. The appraisal is based on HTA, no special criteria are applied. Increasing number of requests have been received in recent times.
  - b) medicines outside out-patient reimbursement list: free pricing
  - c) medicines inpatient: listed on the general reimbursement list, same price increase procedure than for out-patient medicines
- 3) **Introduction or discussion of other measures related to current challenges** (high inflation rates, budget caps, high-priced medicines, introduction of production sites in Europe, etc.):
  - no further measures have been introduced